Fukushima Translational Research Project

Contract Research & Provision

F-PDX®

Fukushima patient-derived tumor xenograft

Patient-derived tumor xenograft established from Japanese patients in Fukushima project.



Features

- ☑ **274 F-PDX® lines have been established.**
  Hematopoietic tumor: 76, Solid tumor: 198
- ☑ **Retention of characteristics of source tumor tissues has been confirmed by both histopathological and comprehensive gene expression analyses.**
- ☑ **Based on histopathological examination, comprehensive gene expression profile, genome analysis, duration from transplantation to engraftment, tumor growth rate, clinical information for the source tumor tissue, HLA type, and other data, F-PDX® lines can be selected according to each intended use.**
- ☑ **F-PDX® lines have been confirmed to be negative for human infectious pathogens, such as hepatitis B and C viruses, human T-lymphotropic virus, human immunodeficiency viruses, *Treponema pallidum*, and parvovirus B19.**

Contact information

Fukushima Translational Research Foundation

Email address
tlo@ftrf.jp

Website
https://ftrf.jp/en/overview-eng/

Human multiple myeloma (MM) xenograft model



Kaplan-Meier curve of survival rate in the MM xenografts.



Punched-out lesions (red area) were clearly observed in femur, tibia, coxa and sacral vertebra of the mice using the three dimensional CT imaging.

F-PDX® lines

Hematopoietic tumor: 76			
Lymphocytic leukemia	57	Acute myeloid leukemia	15
Multiple myeloma	1	Others	3

Solid tumor: 198			
Laryngeal cancer	1	Brain neoplasms	9
Lung cancer	21	Breast cancer	2
Esophageal cancer	1	Gastric cancer	2
Colorectal cancer	16	Anal canal cancer	1
Pancreatic cancer	6	Bile duct cancer	2
Gallbladder cancer	2	Ovarian cancer	26
Fallopian tube cancer	2	Cervical cancer	22
Uterine corpus cancer	45	Peritoneal cancer	4
Choriocarcinoma	1	Kidney cancer	4
Testicular tumor	1	Melanoma	7
Sarcoma	21	Mesothelioma	2

Issued on October 1, 2025